Erratum to: Cancer Chemother Pharmacol (2015) 76:925–932 DOI 10.1007/s00280-015-2850-4
The original version of this article unfortunately contained a mistake. The affiliations of Lee S. Rosen, Jonathan W. Goldman, Hirokazu Mizuguchi, Fabio Benedetti, and Christopher Zergebel are incorrect. The correct affiliations should be:
Lee S. Rosen and Jonathan W. Goldman
University of California, 2020 Santa Monica Blvd., Suite 600, Santa Monica, CA 90404, USA
Hirokazu Mizuguchi, Fabio Benedetti, and Christopher Zergebel
Taiho Oncology Inc., 202 Carnegie Center, Suite 100, Princeton, NJ 08540, USA
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s00280-015-2850-4.
Rights and permissions
About this article
Cite this article
Bendell, J.C., Rosen, L.S., Mayer, R.J. et al. Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemother Pharmacol 77, 439 (2016). https://doi.org/10.1007/s00280-015-2890-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-015-2890-9